RE-BVS – Piemonte Repository

Sfoglia per AUTORE
VISENTIN A
Collezione AO Cuneo

Items : 3

Ventilatory associated barotrauma in COVID-19 patients: A multicenter observational case control study (COVI-MIX-study). in Pulmonology / Pulmonology. 2023 Nov-Dec;29(6):457-468. doi: 10.1016/j.pulmoe.2022.11.002. Epub 2022 Nov 24.

2023
ASL Asti
AO Cuneo

Zuccon U; Visentin A; Vianello A; Viale P; Vania E; Tazza B; Sibani M; Tacconelli E; Tartaglione G; Scarda A; Scabini S; Ruaro B; Salton F; Righi E; Rescigno C; Pettenuzzo T; Quyen NH; Pol R; Nava S; Mura M; Mongodi S; Morosi S; Lupia T; Matellon C; Mehrabi S; Lococo S; Labate L; Granozzi B; Giacobbe DR; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. in Leukemia & lymphoma / Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27.

2022
AO Cuneo
AOU Città della Salute di Torino

Tedeschi A; Montillo M; Zamprogna G; Marinoni S; Ferrario A; Tani M; Varettoni M; Borella C; Ferrarini I; Sanna A; Motta M; Ibatici A; Orsucci L; Massaia M; Vitale C; Vanazzi A; Mauro FR; Quaresmini G; Visentin A; Reda G; Murru R; Laurenti L; Sportoletti P; Frustaci AM; Deodato M;